Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Increasing number of pipeline drug molecules are drive the growth of Hospital Infection Therapeutics Market

Transparency Market Research
Posted on: 19 Sep 16
Increasing number of pipeline drug molecules are drive the growth of Hospital Infection Therapeutics Market

A new market research study, titled “Hospital Infection Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020,” has been published by Transparency Market Research, providing a comprehensive analysis of the market. The major driving factors, barriers, and current trends of the global hospital infection therapeutics market have been included in the scope of the research report.

The report projects the global market for hospital infection therapeutics to attain an opportunity worth US$3.6 bn by 2020, rising from US$3.0 bn in 2013 at a CAGR of 3.10% during the period from 2014 to 2020.

Get Free Sample of Research Report at -

Hospital Infection Therapeutics to Gain Impetus from Increasing Incidence of Hospital-Acquired Infections

“Hospital-acquired infections have been considered as one of the prime threats to human health by healthcare organizations around the world,” says an analyst at TMR. According to the WHO, of the overall pool of hospitalized patients, 7% patients in developed economies and 10% in emerging economies were diagnosed with at least one form of hospital-acquired infections in 2013.

As the prevalence these infections is increasing significantly, the demand for hospital infection therapeutics is witnessing a substantial rise worldwide. Apart from this, the high susceptibility to infections among newborn babies in a healthcare setting is also fueling the application of hospital infection therapeutics across the world.

Inefficiency of Hospital Infection Therapeutics on Multi-drug Resistant Bacterial Strains to Limit Application

Though analysts predict the demand for hospital infection therapeutics to register a steady progress in the near future, a number of factors are likely to interrupt the growth trajectory. The main among them is the robust rise in the number of multi-drug resistant bacterial strains, on which the currently available antibacterial drugs are ineffective. The poor management of antibiotic resistance is leading to a decline in the adoption of hospital infection therapeutics, which is projected to impact negatively on the market’s growth in the long run.

The high unmet medical needs in low to medium income nations, however, is anticipated to present potential growth opportunities to market players. Economies in Southeast Asia and Sub-Saharan Africa demonstrate a high prevalence of hospital-acquired infections among newborns, which has affected the birth rate in these nations significantly. The infrastructural development of the medical and healthcare industry in these economies will also open new avenues for market’s progressions in the near future, states the report.

Currently, North America leads the overall market and is estimated to remain in the leading position in the next few years. North America is closely trailed by Europe. The rapid growth of these two regional markets can be attributed to the increasing healthcare awareness and growing demand for advanced drugs. On the other hand, the Asia Pacific market for hospital infection therapeutics is estimated to witness the fastest growth throughout the forecast period.

Furthermore, the research report talks about the competitive scenario of the global market for hospital infection therapeutics. Detailed profiles of the prominent players have been discussed in the scope of the research study. Some of the leading players operating in the market are Bayer AG, Johnson & Johnson Services, Inc., Actavis plc, Sanofi, Bristol-Myers Squibb Company, Merck & Co., Inc., GlaxoSmithKline plc, Pfizer, Inc., AstraZeneca plc, and Cubist Pharmaceuticals, Inc.

The global hospital infection therapeutics market is segmented as follows:

By Drug Type

    Antibacterial Drugs

    Antiviral Drugs

    Antifungal Drugs

By Major Infections

    Hospital-Acquired Pneumonia

    Surgical Site Infections

    Urinary Tract Infections

    Gastrointestinal Disorders

    Bloodstream Infections

    Other Hospital Infections

By Region

    North America


    Asia Pacific

    Rest of the World (RoW)

For more information:

Editor's Details

Ankit jain
Transparency Market Research

Last updated on: 19/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.